Ovarian (epithelial), fallopian and peritoneal cancer - pazopanib (maintenance) [ID545]
In development [GID-TAG444] Expected publication date: TBC
Search results
575 results
-
-
Breast cancer - intensity modulated radiotherapy [ID16]
In development [GID-TAG390] Expected publication date: TBC
-
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]
In development [GID-TAG393] Expected publication date: TBC
-
Hypercholesterolemia - mipomersen [ID524]
In development [GID-TAG437] Expected publication date: TBC
-
Breast cancer (advanced or metastatic) - lapatinib [ID20]
In development [GID-TAG387] Expected publication date: TBC
-
T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]
In development [GID-TAG433] Expected publication date: TBC
-
Thrombophilia [ID393]
In development [GID-TAG374] Expected publication date: TBC
-
Systemic lupus erythematosus - prasterone [ID392]
In development [GID-TAG373] Expected publication date: TBC
-
Falls - faller's clinics [ID103]
In development [GID-TAG375] Expected publication date: TBC
-
Breast cancer (ErbB2 HER2, metastatic) - lapatinib (with paclitaxel, 1st line) [ID517]
In development [GID-TAG436] Expected publication date: TBC
-
Lung cancer (non-small-cell) - cetuximab [ID9]
In development [GID-TAG395] Expected publication date: TBC
-
Venous thromboembolism (prevention) - rivaroxaban [ID463]
In development [GID-TAG427] Expected publication date: TBC
-
Multiple sclerosis (relapsing-remitting) - laquinimod [ID560]
In development [GID-TAG337] Expected publication date: TBC
-
Heart failure (acute) - serelaxin [ID673]
In development [GID-TAG454] Expected publication date: TBC
-
Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]
In development [GID-TAG332] Expected publication date: TBC
-
Macular oedema (diabetic) - pegaptanib sodium [ID452]
In development [GID-TAG280] Expected publication date: TBC
-
Venous thromboembolism - apixaban (acute medical illness) [ID310]
In development [GID-TAG419] Expected publication date: TBC
-
Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]
In development [GID-TAG417] Expected publication date: TBC
-
Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib [ID115]
In development [GID-TAG404] Expected publication date: TBC
-
Lung cancer (non-small-cell, untreated) - paclitaxel formulated as albumin-bound nanoparticles (with carboplatin) [ID553]
In development [GID-TAG528] Expected publication date: TBC
-
Juvenile idiopathic arthritis - abatacept [ID27]
In development [GID-TAG402] Expected publication date: TBC
-
Glioblastoma - bevacizumab [ID80]
In development [GID-TAG413] Expected publication date: TBC
-
Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622
In development [GID-TAG360] Expected publication date: TBC
-
Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]
In development [GID-TAG424] Expected publication date: TBC
-
Multiple myeloma - bortezomib (consolidation therapy) [ID529]
In development [GID-TAG320] Expected publication date: TBC
-
Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]
In development [GID-TAG435] Expected publication date: TBC
-
Generalised anxiety disorder - quetiapine [ID347]
In development [GID-TAG421] Expected publication date: TBC
-
Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]
In development [GID-TA10390] Expected publication date: TBC
-
Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]
In development [GID-TA10546] Expected publication date: TBC
-
Durvalumab for untreated EGFR-negative, ALK-negative non-small-cell lung cancer ID1331
In development [GID-TA10318] Expected publication date: TBC
-
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169
In development [GID-TA10324] Expected publication date: TBC
-
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer ID1335
In development [GID-TA10315] Expected publication date: TBC
-
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
In development [GID-TA10418] Expected publication date: TBC
-
Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]
In development [GID-TA10121] Expected publication date: TBC
-
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]
In development [GID-TA10473] Expected publication date: TBC
-
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck ID1355
In development [GID-TA10321] Expected publication date: TBC
-
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565
In development [GID-TA10502] Expected publication date: TBC
-
Nintedanib for previously treated metastatic colorectal cancer [ID1030]
In development [GID-TA10138] Expected publication date: TBC
-
Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]
In development [GID-TA10140] Expected publication date: TBC
-
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]
In development [GID-TA10144] Expected publication date: TBC
-
NGR-TNF for previously treated advanced malignant pleural mesothelioma (ID655)
In development [GID-TA10183] Expected publication date: TBC
-
Nivolumab for treating recurrent glioblastoma [ID998]
In development [GID-TA10126] Expected publication date: TBC
-
Multiple sclerosis (primary-progressive) - fingolimod [ID62]
In development [GID-TAG221] Expected publication date: TBC
-
Pelareorep for treating recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer [ID1099]
In development [GID-TA10688] Expected publication date: TBC
-
NBTXR-3 for treating soft tissue sarcoma [ID1050]
In development [GID-TA10226] Expected publication date: TBC
-
L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]
In development [GID-TA10452] Expected publication date: TBC
-
Nivolumab monotherapy for non-small-cell lung cancer [ID1088]
In development [GID-TA10148] Expected publication date: TBC
-
Nivolumab with radiation therapy for untreated glioblastoma ID1562
In development [GID-TA10443] Expected publication date: TBC
-
Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer (ID1135)
In development [GID-TA10233] Expected publication date: TBC
-
Brentuximab vedotin for untreated advanced Hodgkin lymphoma [1258]
In development [GID-TA10224] Expected publication date: TBC